Derniers essais


EudraCT Number: 2022-001393-58 Sponsor Protocol Number: T21-118 Start Date: 2023-04-13
Sponsor Name: Hagaziekenhuis
Full Title: POMPAE trial: Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated.
Medical condition: Atrial fibrillation
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2022-001297-63 Sponsor Protocol Number: ML-ORI-201 Start Date: 2023-04-13
Sponsor Name: Melinta Therapeutics, LLC
Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects...
Medical condition: Acute Bacterial Skin and Skin Structure Infections
Disease: Version SOC Term Classification Code Term Level
Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: BG (Ongoing) LT (Ongoing) LV (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-003065-38 Sponsor Protocol Number: 1102-DMD-Pre-CT03 Start Date: 2023-04-13
Sponsor Name: Antisense Therapeutics Limited
Full Title: A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by ...
Medical condition: Duchenne Muscular Dystrophy
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
Population Age: Children, Adolescents, Under 18 Gender: Male
Trial protocol: BG (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002524-12 Sponsor Protocol Number: BNZ-20-01-2022 Start Date: 2023-04-13
Sponsor Name: AZAD Pharma AG
Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br...
Medical condition: GLAUCOMA , OCCULAR HYPERTENSION
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BG (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2022-002014-16 Sponsor Protocol Number: VIR-MHB1-V200 Start Date: 2023-04-12
Sponsor Name: Vir Biotechnology, Inc.
Full Title: A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)
Medical condition: Chronic Hepatitis B Virus (HBV) Infection
Disease: Version SOC Term Classification Code Term Level
20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
Population Age: Adults Gender: Male, Female
Trial protocol: BG (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2022-002751-19 Sponsor Protocol Number: 82160 Start Date: 2023-04-11
Sponsor Name: Amsterdam UMC
Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients
Medical condition: Inflammatory Bowel Diseases
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002746-40 Sponsor Protocol Number: VX22-864-108 Start Date: 2023-04-11
Sponsor Name: Vertex Pharmaceuticals Incorporated
Full Title: A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks
Medical condition: Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype
Disease: Version SOC Term Classification Code Term Level
23.1 10010331 - Congenital, familial and genetic disorders 10083869 Alpha-1 antitrypsin deficiency PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2022-002965-13 Sponsor Protocol Number: TAK-861-2003 Start Date: 2023-04-11
Sponsor Name: Takeda Development Center Americas, Inc.
Full Title: A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions
Medical condition: Narcolepsy with Cataplexy (Type 1) and Narcolepsy without Cataplexy (Type 2)
Disease: Version SOC Term Classification Code Term Level
20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NO (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) SE (Ongoing) FI (Ongoing)
Trial results: (No results available)
EudraCT Number: 2018-001189-40 Sponsor Protocol Number: APD811-303 Start Date: 2023-04-05
Sponsor Name: Arena Pharmaceuticals, Inc.
Full Title: A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
Medical condition: Pulmonary arterial hypertension (PAH)
Disease: Version SOC Term Classification Code Term Level
20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Ongoing) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Ongoing) BE (Ongoing) DK (Ongoing) NL (Ongoing) HU (Ongoing) BG (Ongoing) GR (Ongoing) PL (Ongoing) PT (Ongoing) HR (Ongoing) IT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001547-25 Sponsor Protocol Number: ZILO-301 Start Date: 2023-04-04
Sponsor Name: Oncternal Therapeutics, Inc
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects with Relapsed or Refractory Ma...
Medical condition: Relapsed or Refractory Mantle Cell Lymphoma
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026801 Mantle cell lymphoma refractory PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026800 Mantle cell lymphoma recurrent PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: HU (Prematurely Ended) ES (Ongoing)
Trial results: (No results available)